英夫利西单抗治疗强直性脊柱炎的临床疗效及安全性观察

Clinical effects and safety of infliximab in the treatment of ankylosing spondylitis

目的探讨英夫利昔单抗治疗强直性脊柱炎的临床疗效和安全性。方法选择本院收治的68例强直性脊柱炎患者的临床资料,随机分为对照组(33例)和观察组(35例)。对照组患者采用传统药物进行治疗,而观察组患者采用传统药物加上英夫利昔单抗进行治疗,比较2组患者的临床疗效和不良反应发生情况。结果治疗后,观察组患者的总有效率为94.29%,明显高于对照组患者。观察组患者的脊柱晨僵持续时间、疼痛程度、ESR、CRP等指标均较对照组患者得到较为明显的改善。结论英夫利昔单抗治疗强直性脊柱炎具有十分显著的疗效,有利于患者预后恢复,值得临床广泛推广和应用。

Objective To investigate the clinical effects and safety of infliximab in the treatment of ankylosing spondylitis. Methods Sixtyeight patients with ankylosing spondylitis of our hospital were randomly divided into control group （ n = 33） and observation group （ n = 35）. The control group was treated with traditional drugs, while the observation group with infliximab besides the traditional drugs. The clinical effects and adverse reactions between the two groups were compared. Results After treatment, the total efficacy rate of the observation group was 94.29 %, remarkably higher than that of the control group. The duration of spinal morning stiffness, degree of pain, ESR and CRP in the observation group all obviously improved compared with those in the control group. Conclusion Infliximab has a very marked therapeutic effect in the treatment of ankylosing spondylitis, and is conducive to patients＇ recovery, so it is worthy of extensive promotion and application.